Terran Biosciences is a biotech platform company devoted to the development of transformative therapeutics and technologies for patients with neurological and psychiatric diseases. Our pipeline includes multiple clinical-stage CNS therapeutics: 1) TerXT: a combination of novel prodrugs of xanomeline and trospium designed to be a long-acting treatment for schizophrenia with potential for accelerated 505(b)(2) approval. 2) Idazoxan XR: a once-daily oral therapeutic with a novel mechanism (alpha 2 antagonist) for the treatment of schizophrenia, currently in a clinical study. 3) A fixed dose combination of a psychedelic with a serotonin receptor antagonist for the treatment of depression. In addition to these innovations, Terran’s drug design and chemistry engine has created a robust psychedelic-based therapeutics pipeline covered by granted patents and designed for the 505(b)(2) pathway.